文献速递淋巴瘤白血病

奈玛特韦联合利托那韦治疗慢性淋巴细胞白血病患者在奥密克戎高峰期的有效性

Effectiveness of nirmatrelvir plus ritonavir treatment for patients with chronic lymphocytic leukemia during the Omicron surge.
PubMed 文献 · Blood · 2023-01-01

本研究回顾性评估奈玛特韦联合利托那韦在1080例感染严重急性呼吸综合征冠状病毒2的慢性淋巴细胞白血病患者中的有效性。治疗组第35天COVID-19相关住院或死亡率为4.8%(14/292),未治疗组为10.2%(75/733)。年龄≥65岁患者相对风险降低69%。

要点

  • 奈玛特韦给药与第35天COVID-19相关住院或死亡减少相关。
  • 治疗组COVID-19相关住院或死亡率4.8%(14/292) vs 未治疗组10.2%(75/733)。
  • 年龄≥65岁慢性淋巴细胞白血病患者相对风险降低69%。

核心结论

  • 奈玛特韦给药与慢性淋巴细胞白血病患者第35天COVID-19相关住院或死亡减少相关。
  • 年龄≥65岁患者中报告COVID-19相关住院或死亡相对风险降低69%。

研究设计与样本

  • 回顾性评估奈玛特韦联合利托那韦在1080例感染严重急性呼吸综合征冠状病毒2的慢性淋巴细胞白血病患者中的有效性。

主要发现

  • 治疗组COVID-19相关住院或死亡率为4.8%(14/292),未治疗组为10.2%(75/733)。
  • 年龄≥65岁慢性淋巴细胞白血病患者相对风险降低69%。
  • 多因素分析表明年龄>65岁、接受过重度治疗(既往治疗>2种)、近期住院、静脉注射免疫球蛋白治疗和合并症的患者在接受奈玛特韦治疗后结局有显著改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with chronic lymphoid leukemia (CLL), even in the Omicron era and after vaccination, suffer from persistent COVID-19 infection, higher complications, and mortality compared with the general population. In this study, we evaluated retrospectively the effectiveness of nirmatrelvir + ritonavir among 1080 patients with CLL who were infected with severe acute respiratory syndrome coronavirus 2. Nirmatrelvir administration was associated with a reduction in COVID-19-related hospitalization or death by day 35. Specifically, the rate of COVID-19-related hospitalization or death in the treated group compared with the untreated group was 4.8% (14 out of 292) vs 10.2% (75 out of 733), respectively. Moreover, we report a 69% relative risk reduction in COVID-19-related hospitalization or death in patients with CLL at the age of ≥65 years. Multivariate analysis indicates that patients aged >65 years, patients who received heavy treatment (>2 previous treatments), patients with recent hospitalizations, intravenous immunoglobulin (IVIG) treatment, and comorbidity had significant improvement outcomes after treatment with nirmatrelvir.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Tadmor T, Alapi H, Rokach L, et al. Effectiveness of nirmatrelvir plus ritonavir treatment for patients with chronic lymphocytic leukemia during the Omicron surge. Blood. 2023. PMID: 36848657. doi:10.1182/blood.2022019017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。